Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection.

Zhang Q, Donohue-Rolfe A, Krautz-Peterson G, Sevo M, Parry N, Abeijon C, Tzipori S.

J Infect Dis. 2009 Feb 15;199(4):486-93. doi: 10.1086/596509.

2.

Subtype-specific suppression of Shiga toxin 2 released from Escherichia coli upon exposure to protein synthesis inhibitors.

Pedersen MG, Hansen C, Riise E, Persson S, Olsen KE.

J Clin Microbiol. 2008 Sep;46(9):2987-91. doi: 10.1128/JCM.00871-08. Epub 2008 Jul 23.

3.

Differentiation between structurally homologous Shiga 1 and Shiga 2 toxins by using synthetic glycoconjugates.

Kale RR, McGannon CM, Fuller-Schaefer C, Hatch DM, Flagler MJ, Gamage SD, Weiss AA, Iyer SS.

Angew Chem Int Ed Engl. 2008;47(7):1265-8. doi: 10.1002/anie.200703680. No abstract available.

PMID:
18172842
4.

Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.

Ochoa TJ, Chen J, Walker CM, Gonzales E, Cleary TG.

Antimicrob Agents Chemother. 2007 Aug;51(8):2837-41. Epub 2007 May 25.

5.
6.
7.

Commensal bacteria influence Escherichia coli O157:H7 persistence and Shiga toxin production in the mouse intestine.

Gamage SD, Patton AK, Strasser JE, Chalk CL, Weiss AA.

Infect Immun. 2006 Mar;74(3):1977-83.

8.

Genetic characterization of Escherichia coli O157: H7/- strains carrying the stx2 gene but not producing Shiga toxin 2.

Koitabashi T, Vuddhakul V, Radu S, Morigaki T, Asai N, Nakaguchi Y, Nishibuchi M.

Microbiol Immunol. 2006;50(2):135-48.

9.
10.

Phage regulatory circuits and virulence gene expression.

Waldor MK, Friedman DI.

Curr Opin Microbiol. 2005 Aug;8(4):459-65. Review.

PMID:
15979389
11.

Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Tarr PI, Gordon CA, Chandler WL.

Lancet. 2005 Mar 19-25;365(9464):1073-86. Review.

PMID:
15781103
12.

Diversity and host range of Shiga toxin-encoding phage.

Gamage SD, Patton AK, Hanson JF, Weiss AA.

Infect Immun. 2004 Dec;72(12):7131-9.

13.

CT and MRI in haemolytic uraemic syndrome with central nervous system involvement: distribution of lesions and prognostic value of imaging findings.

Steinborn M, Leiz S, Rüdisser K, Griebel M, Harder T, Hahn H.

Pediatr Radiol. 2004 Oct;34(10):805-10. Epub 2004 Jul 29.

PMID:
15378218
14.

Escherichia coli serogroup O107/O117 lipopolysaccharide binds and neutralizes Shiga toxin 2.

Gamage SD, McGannon CM, Weiss AA.

J Bacteriol. 2004 Aug;186(16):5506-12.

15.
16.

Nonpathogenic Escherichia coli can contribute to the production of Shiga toxin.

Gamage SD, Strasser JE, Chalk CL, Weiss AA.

Infect Immun. 2003 Jun;71(6):3107-15.

17.

Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.

Siegler RL, Obrig TG, Pysher TJ, Tesh VL, Denkers ND, Taylor FB.

Pediatr Nephrol. 2003 Feb;18(2):92-6. Epub 2003 Jan 10.

PMID:
12579394
18.

Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response.

Ohara T, Kojio S, Taneike I, Nakagawa S, Gondaira F, Tamura Y, Gejyo F, Zhang HM, Yamamoto T.

Antimicrob Agents Chemother. 2002 Nov;46(11):3478-83.

19.

The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI.

N Engl J Med. 2000 Jun 29;342(26):1930-6.

20.

Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro.

Murakami J, Kishi K, Hirai K, Hiramatsu K, Yamasaki T, Nasu M.

Int J Antimicrob Agents. 2000 Jul;15(2):103-9.

PMID:
10854805
Items per page

Supplemental Content

Write to the Help Desk